Sugi Predict

Sugi Predict / Compounds / SCHEMBL4655671

SCHEMBL4655671

SCHEMBL4655671

CCCN(CC)c1ccc(-c2nccc3cc(OC)c(OC)cc23)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ MYC P01106 5/20 0.41
▸ PDE10A Q9Y233 4/20 0.39
▸ USP2 O75604 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ PDE3B Q13370 2/20 0.39
▸ PDE3A Q14432 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HIF1A Q16665 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ PDE2A O00408 1/20 0.39
▸ ABCC4 O15439 1/20 0.39
▸ PDE5A O76074 1/20 0.39
▸ ABCB11 O95342 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4655563 0.74 MEN1 (0.55) MEN1KMT2APDE10AUSP2ALDH1A1
SCHEMBL2460475 0.72 MEN1 (0.66) MEN1KMT2APDE10AUSP2ALDH1A1
Hydrochloric Acid SCHEMBL1022954 0.71 MEN1 (0.64) MEN1KMT2APDE10AUSP2ALDH1A1
SCHEMBL30789065 0.71 MEN1 (0.56) MEN1KMT2APDE10AUSP2ALDH1A1
SCHEMBL30789068 0.70 MEN1 (0.59) MEN1KMT2APDE10AUSP2ALDH1A1
SCHEMBL4712213 0.70 PDE10A (0.57) MEN1KMT2APDE10AACHETNF
Octaverine SCHEMBL25619 0.69 MEN1 (1.00) MEN1KMT2APDE10AUSP2ALDH1A1
Octaverine SCHEMBL29706512 0.69 MEN1 (1.00) MEN1KMT2APDE10AUSP2ALDH1A1
Bromide SCHEMBL8002743 0.69 MEN1 (0.60) MEN1KMT2APDE10AUSP2ALDH1A1
SCHEMBL30789062 0.68 MEN1 (0.56) MEN1KMT2APDE10AUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996574-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-12-03 — — EP disclosed
US-20070299067-A1 Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors AMGEN INC. 2007-12-27 — — US disclosed
US-20070299067-A1 Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors AMGEN INC. 2007-12-27 — — US disclosed
US-20070299067-A1 Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors AMGEN INC. 2007-12-27 — — US disclosed
WO-2007103554-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-09-13 — — WO disclosed
WO-2007103554-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-09-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299067-A1 Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors PDE12, PDE10A, PDE4A MEN1 2743/4885KMT2A 2094/4885MYC 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.